Agreements reached under this partnership
Capital and Business Alliance- 1
The Company has acquired sales rights in Japan as one of Craif's sales partners for the sale of Craif's MySignal Scan urine cancer risk test to medical institutions through pharmaceutical and medical device wholesalers and other channels.
- 2
The Company has also acquired exclusive sales rights in Japan for the sale to medical institutions, through the same sales channel, of Craif's pancreatic cancer medical device program (SaMD), currently under development and based on urinary microRNA analysis.
- 3
During the term of the business alliance agreement, the Company has acquired preferential negotiating rights for SaMD products for other types of cancer that are related to or derived from the pancreatic cancer SaMD, as well as SaMD products newly offered for sale in the future.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
At this time, we believe that the execution of this agreement will have a minor impact on our results. If it becomes clear that the agreement will have a material impact, we will promptly disclose the relevant information.
| Item | Details |
|---|---|
| Name of alliance partner | Craif Inc. |
| Alliance partner's business activities | Research and development of next-generation tests for the early detection of diseases, primarily in the cancer field, and the realization of personalized medicine, as well as provision of the MySignal® urine-based cancer risk test |
| Alliance partner's location | Shinjuku-ku, Tokyo |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | The Company has acquired sales rights in Japan as one of Craif's sales partners for the sale of Craif's MySignal Scan urine cancer risk test to medical institutions through pharmaceutical and medical device wholesalers and other channels., The Company has also acquired exclusive sales rights in Japan for the sale to medical institutions, through the same sales channel, of Craif's pancreatic cancer medical device program (SaMD), currently under development and based on urinary microRNA analysis., During the term of the business alliance agreement, the Company has acquired preferential negotiating rights for SaMD products for other types of cancer that are related to or derived from the pancreatic cancer SaMD, as well as SaMD products newly offered for sale in the future. |
| Contract Date | July 2026 (business alliance agreement) |
| Alliance start date | July 2026 (business alliance agreement) |
| Impact on Business Performance | At this time, we believe that the execution of this agreement will have a minor impact on our results. If it becomes clear that the agreement will have a material impact, we will promptly disclose the relevant information. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To enable Craif to strengthen its research and development capabilities in the United States and launch products with a view to securing insurance reimbursement there, while advancing the research and development and business development of MySignal in Japan and the clinical development of its pancreatic cancer medical device program, and accelerating the construction of a urine analysis platform.